UNSPSC 51293000: Antidepressant dibenzocycloheptenes

Antidepressant drugs made from a family of tricyclic hydrocarbons whose members include many of the commonly used tricyclic antidepressants.

UNSPSC 51293000 Antidepressant dibenzocycloheptenes is a Class code that in recent state and local procurement activity encompasses a broader range of pharmaceutical products and drug-related services than the code's nominal scope suggests. Recent solicitations show state and local governments buying naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing vehicles, and exploring direct-to-manufacturer prescription programs to improve pharmacy benefit management and cost efficiency. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota MMCAP administering on behalf of participating state and local facilities including Oregon). The work spans procurement of finished pharmaceutical products with specific National Drug Codes, establishment of ongoing supply contracts with authorized wholesalers, and exploratory market research on alternative pharmacy benefit delivery models.

Recent activity concentrates in the South (Florida) and Upper Midwest (Minnesota, Oregon), with emerging procurement in Texas. Representative opportunities include Seminole County's IFB60459723LAS (released June 30, 2026, response deadline July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) seeking vendor capability information on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements; and the Minnesota MMCAP RFP S1070000015802 (posted January 20, 2026, response deadline March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with contract effectiveness July 1, 2026 and weighted evaluation favoring price competitiveness at 75 percent. All three solicitations require vendors to meet FDA and Drug Supply Chain Security Act compliance, maintain specified insurance, and commit to fixed pricing or negotiated net-pricing models over multi-year terms.